Wall Street isn’t (yet) getting that ABT is the leader of the pack in all-oral HCV, at least for genotype-1. GILD and BMY are duking it out for the privilege of being #2, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.